Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Irene L. M. Reijers; Alexander M. Menzies; Alexander C. J. van Akkooi; Judith M. Versluis; N.M.J. Van Den Heuvel; Robyn P.M. Saw; Thomas E. Pennington; Ellen Kapiteijn; Astrid A.M. van der Veldt; Karijn P.M. Suijkerbuijk; Geke A.P. Hospers; Elisa A. Rozeman; W. Martin C. Klop; Winan J. van Houdt; Karolina Sikorska; Jos A. van der Hage; Dirk J. Grünhagen; Michel W.J.M. Wouters; Arjen J. Witkamp; Charlotte L. Zuur; J. Lijnsvelt; A. Torres Acosta; Lindsay G. Grijpink-Ongering; Maria Gonzalez; Katarzyna Jóźwiak; Carolien Bierman; Kerwin F. Shannon; Sydney Ch’ng; Andrew J. Colebatch; Andrew J. Spillane; John B.A.G. Haanen; Robert V. Rawson; Bart A. van de Wiel; Lonneke V. van de Poll‐Franse; Richard A. Scolyer; Annelies H. Boekhout; Georgina V. Long; Christian U. Blank

doi:10.1038/s41591-022-01851-x

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Irene L. M. Reijers(The Netherlands Cancer Institute), Alexander M. Menzies(The University of Sydney), Alexander C. J. van Akkooi(The University of Sydney), Judith M. Versluis(The Netherlands Cancer Institute), N.M.J. Van Den Heuvel(The Netherlands Cancer Institute), Robyn P.M. Saw(The University of Sydney), Thomas E. Pennington(The University of Sydney), Ellen Kapiteijn(Leiden University Medical Center), Astrid A.M. van der Veldt(Erasmus MC), Karijn P.M. Suijkerbuijk(University Medical Center Utrecht), Geke A.P. Hospers(University Medical Center Groningen), Elisa A. Rozeman(The Netherlands Cancer Institute), W. Martin C. Klop(The Netherlands Cancer Institute), Winan J. van Houdt(The Netherlands Cancer Institute), Karolina Sikorska(The Netherlands Cancer Institute), Jos A. van der Hage(Leiden University Medical Center), Dirk J. Grünhagen(Erasmus MC Cancer Institute), Michel W.J.M. Wouters(Leiden University Medical Center), Arjen J. Witkamp(University Medical Center Utrecht), Charlotte L. Zuur(Leiden University Medical Center), J. Lijnsvelt(The Netherlands Cancer Institute), A. Torres Acosta(The Netherlands Cancer Institute), Lindsay G. Grijpink-Ongering(The Netherlands Cancer Institute), Maria Gonzalez(The University of Sydney), Katarzyna Jóźwiak(Medizinische Hochschule Brandenburg Theodor Fontane), Carolien Bierman(The Netherlands Cancer Institute), Kerwin F. Shannon(The University of Sydney), Sydney Ch’ng(The University of Sydney), Andrew J. Colebatch(The University of Sydney), Andrew J. Spillane(The University of Sydney), John B.A.G. Haanen(Leiden University Medical Center), Robert V. Rawson(The University of Sydney), Bart A. van de Wiel(The Netherlands Cancer Institute), Lonneke V. van de Poll‐Franse(Tilburg University), Richard A. Scolyer(The University of Sydney), Annelies H. Boekhout(The Netherlands Cancer Institute), Georgina V. Long(The University of Sydney), Christian U. Blank(Leiden University Medical Center)

Nature Medicine

June 1, 2022

10.1038/s41591-022-01851-x

Cited by 348Open Access

Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis